The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has filed a Form 8.3 in relation to Avadel Pharmaceuticals plc. This disclosure pertains to the company's interests in relevant securities under Rule 8.3 of the Irish Takeover Panel Act, 1997. As of November 19, 2025, Vanguard owns 5,563,719 ordinary shares, representing a 5.71% stake in Avadel.

In recent transactions, Vanguard purchased an additional 586 ordinary shares of Avadel at a price of 23.10 USD per share. There were no cash-settled or stock-settled derivative transactions reported.

The disclosure further confirms the absence of any indemnity or other arrangements related to dealing inducements, options, or derivatives associated with Avadel's securities. No Supplemental Form 8 was attached to this filing. The disclosure does not relate to any other party involved in the offer, as it is not a cash offer.